MiMedx Group Inc
MDXG evidence brief
What we can confirm
- BioSniper Score:
- 8.0 / 10
- Market Cap:
- $681.5M
- Lead Asset:
- AMNIOFIX (Approved)
What it means
What to watch
Prepared research question
What matters most for MDXG—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MDXG
MiMedx Group Inc is a regenerative medicine company that develops and markets placental-derived allografts for wound care and surgical applications, with a recent strategic shift toward its Surgical portfolio amid declining Wound product sales.
Key risk: Wound revenue decline
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$681.5M
Cash Runway
—
Lead Asset
AMNIOFIX (Approved)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 2 clinical trials for MiMedx Group Inc.
MiMedx Group Inc is a regenerative medicine company that develops and markets placental-derived allografts for wound care and surgical applications, with a recent strategic shift toward its Surgical portfolio amid declining Wound product sales.
- Net sales grew 20% in 2025, driven by strong Wound product growth and continued adoption of Surgical offerings [sec · filed 2026-04-29].
- In Q2 2026, total net sales were $64M, a 35% decrease year-over-year, with Wound sales down 61% and Surgical sales up 15% [sec_mda · as of 2026-07-29].
- Cash & equivalents were $135.8M as of 2026-06-30 [sec]; net loss was $14.8M for the quarter ended 2026-06-30 [sec].
- The company launched EPIXPRESS in late 2025 and has distribution agreements for several wound care products [sec · filed 2026-04-29].
- Surgical business posted a sixth consecutive quarter of double-digit year-over-year growth in Q2 2026 [sec_mda · as of 2026-07-29].
What works
- Surgical portfolio has shown consistent double-digit year-over-year growth for six consecutive quarters as of Q2 2026 [sec_mda · as of 2026-07-29].
- The company generated $74M in operating cash flow and $73M in free cash flow in 2025, with an Adjusted EBITDA margin of 25% [sec · filed 2026-04-29].
- New product launches (EPIXPRESS) and distribution agreements (RegenKit, Hydrelix, NovaForm, G4Derm Plus) are expanding the product portfolio [sec · filed 2026-04-29].
What to weigh
- Wound product sales declined 61% in Q2 2026 year-over-year, driven by reimbursement headwinds and sales force turnover [sec_mda · as of 2026-07-29].
- Total net sales decreased 35% in Q2 2026 compared to the prior year period, reflecting ongoing challenges in the Wound category [sec_mda · as of 2026-07-29].
- The company reported a GAAP net loss of $14.8M for the quarter ended 2026-06-30 [sec].
- Reimbursement environment for Wound products remains uncertain, with CMS delays in implementing reform [sec · filed 2026-04-29].
From the filings
Quoted directly from source documents.
Surgical business grew double-digits for six consecutive quarters
“Surgical business, which demonstrated a sixth consecutive quarter of double-digit year-over-year growth”
SEC MD&A · July 29, 2026
Net sales grew 20% in 2025
“Our net sales grew 20% in 2025”
SEC filings · April 29, 2026
Wound sales declined 61% in Q2 2026
“a 61% decline in Wound sales”
SEC MD&A · July 29, 2026
EPIXPRESS launched in late 2025
“late-2025 launch of EPIXPRESS”
SEC filings · April 29, 2026
Risks & what to watch (4)›
Key risks
- Wound revenue decline — Wound sales fell 61% in Q2 2026 due to reimbursement pressures and competition [sec_mda · as of 2026-07-29].
- Reimbursement uncertainty — CMS delay in implementing reimbursement reform creates ongoing pricing and access risk for Wound products [sec · filed 2026-04-29].
- Sales force turnover — Departure of sales professionals to competitors offering higher-priced products has impacted Wound sales [sec · filed 2026-04-29].
- Net loss in Q2 2026 — GAAP net loss of $14.8M for the quarter ended 2026-06-30 [sec].
What to watch
- Surgical portfolio growth trajectory and whether it can offset Wound declines [sec_mda · as of 2026-07-29].
- Reimbursement environment for Wound products, including any CMS policy changes [sec · filed 2026-04-29].
- Adoption of new products like EPIXPRESS and distribution agreements [sec · filed 2026-04-29].
- Cash position and share repurchase activity; $12.5M spent on repurchases in Q2 2026 [sec_mda · as of 2026-07-29].
Sources: Pipeline · SEC filings · SEC MD&A · Generated October 8, 2026 · How we verify sources →
Run MiMedx Group Inc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available MiMedx Group Inc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.30 · 0% dilution
Lead: Approved
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of May 21, 2026- % of float
- 7.1%
- Days to cover
- 4.9
- Shares short
- 8,389,116
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MDXG short interestGovernance
Frequently asked questions
What is the AI investment thesis for MiMedx Group Inc?
MiMedx Group Inc is a regenerative medicine company that develops and markets placental-derived allografts for wound care and surgical applications, with a recent strategic shift toward its Surgical portfolio amid declining Wound product sales.
What is MiMedx Group Inc's lead drug candidate?
MiMedx Group Inc's most advanced tracked candidate is AMNIOFIX (Approved) for Liver Transplant.
Who is the CEO of MiMedx Group Inc?
Mr. Joseph H. Capper is the chief executive officer of MiMedx Group Inc (MDXG).
Where is MiMedx Group Inc headquartered?
MiMedx Group Inc (MDXG) is headquartered in Marietta, GA, United States.
What therapeutic areas does MiMedx Group Inc focus on?
MiMedx Group Inc develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.